Index
RUT
Market Cap
10.19B
Enterprise Value
9.30B
Income
-349.43M
Sales
102.23M
Book/sh
18.92
Cash/sh
11.38
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
238
IPO
Aug 21, 2020
P/E
-
Forward P/E
-
PEG
-
P/S
99.70
P/B
6.31
P/C
10.49
P/FCF
-
EV/EBITDA
-
EV/Sales
90.95
Quick Ratio
11.13
Current Ratio
11.13
Debt/Eq
0.05
LT Debt/Eq
0.04
Option/Short
Yes / Yes
EPS (ttm)
-3.62
EPS next Y
-5.22
EPS next Q
-1.30
EPS this Y
-7.69%
EPS next Y
-31.23%
EPS next 5Y
-16.09%
EPS past 3/5Y
-8.68% -3.19%
Sales past 3/5Y
-5.74% 2.87%
EPS Y/Y TTM
-0.64%
Sales Y/Y TTM
133.77%
EPS Q/Q
-40.09%
Sales Q/Q
-100.00%
Insider Own
10.18%
Insider Trans
-29.53%
Inst Own
109.41%
Inst Trans
1.39%
ROA
-24.36%
ROE
-27.29%
ROIC
-20.83%
Gross Margin
92.07%
Oper. Margin
-396.04%
Profit Margin
-341.79%
SMA20
-5.19%
SMA50
1.56%
SMA200
18.95%
Trades
Shs Outstand
85.33M
Shs Float
76.68M
52W High
142.92 -16.46%
52W Low
63.69 87.45%
Volatility
4.88% 5.77%
ATR (14)
6.56
RSI (14)
45.39
Beta
2.03
Rel Volume
0.86
Avg Volume
838.02K
Volume
723,247
Perf Week
-6.12%
Perf Month
6.00%
Perf Quarter
-0.34%
Perf Half Y
48.11%
Perf YTD
53.44%
Perf Year
84.19%
Perf 3Y
514.46%
Perf 5Y
94.13%
Perf 10Y
-
Prev Close
121.13
Price
119.39
Change %
-1.44%
Analysts 15 incl. previous ratings
Rating Distribution 14 Buy · 1 Hold · 0 Sell
Date Action Analyst Rating Change Price Target Change Implied Upside Oct 09, 2026 Initiated R Raymond James
Outperform $140 +17.3% Sep 10, 2026 Upgrade W Wolfe Research
Peer Perform → Outperform $180 +50.8% Jul 30, 2026 Initiated D Deutsche Bank
Hold $120 +0.5% May 06, 2026 Initiated C Canaccord Genuity
Buy $106 -11.2% Mar 16, 2026 Resumed J Jefferies
Buy Jan 28, 2026 Resumed B Barclays
Overweight $133 +11.4% Jan 06, 2026 Downgrade W Wolfe Research
Outperform → Peer Perform Nov 03, 2025 Resumed G Guggenheim
Buy $90 -24.6% Oct 24, 2025 Reiterated R B. Riley Securities
Buy $60 → $80 -33.0% Oct 21, 2025 Initiated M Mizuho
Outperform $81 -32.2% Sep 18, 2025 Reiterated H H.C. Wainwright
Buy $60 → $70 -41.4% Sep 17, 2025 Initiated B Barclays
Overweight $60 -49.7% Sep 16, 2025 Initiated R RBC Capital Mkts
Outperform $70 -41.4% Jul 30, 2025 Resumed R B. Riley Securities
Buy $60 -49.7% Jul 03, 2025 Resumed M Morgan Stanley
Overweight $70 -41.4% Jun 03, 2025 Upgrade M Morgan Stanley
Equal-Weight → Overweight $79 -33.8% Jun 03, 2025 Upgrade R B. Riley Securities
Neutral → Buy $60 -49.7% Jun 02, 2025 Upgrade B BofA Securities
Neutral → Buy $51 -57.3% May 20, 2025 Resumed S Stifel
Buy $55 -53.9% Mar 13, 2025 Initiated C Citigroup
Buy $52 -56.4%
Show Previous Ratings
Oct-29-26 12:22PM
07:00AM
Oct-28-26 04:01PM
Oct-22-26 07:37PM
04:01PM
05:30AM
Loading…
Oct-15-26 05:30AM
(The Wall Street Journal)
Sep-02-26 04:01PM
Sep-01-26 07:00AM
Aug-05-26 07:00AM
Aug-04-26 09:23AM
Jul-30-26 09:38AM
Jul-28-26 04:01PM
Jul-27-26 04:01PM
Jul-13-26 09:41AM
Jul-07-26 07:00AM
04:00AM
Loading…
Jul-03-26 04:00AM
Jun-25-26 07:58PM
(Stocktwits)
+16.61%
-7.16%
11:16AM
(Investor's Business Daily)
07:00AM
Jun-24-26 04:01PM
Jun-12-26 07:00AM
Jun-09-26 07:00AM
Jun-08-26 04:01PM
07:00AM
May-27-26 07:00AM
May-15-26 07:00AM
May-06-26 09:38AM
07:00AM
May-05-26 07:00AM
Apr-30-26 07:00AM
09:20AM
Loading…
Apr-29-26 09:20AM
Apr-23-26 07:00AM
Apr-13-26 07:00AM
Apr-09-26 07:00AM
Mar-28-26 11:00AM
Mar-23-26 08:15AM
Mar-10-26 07:00AM
Mar-09-26 10:38PM
Feb-28-26 01:32PM
Feb-27-26 09:34AM
09:00AM
Feb-26-26 05:03PM
04:08PM
09:55AM
07:00AM
Feb-25-26 07:19AM
Feb-24-26 07:00AM
Feb-19-26 07:00AM
Feb-14-26 01:03AM
Feb-04-26 07:00AM
Jan-30-26 10:11AM
Jan-29-26 07:00AM
Jan-15-26 11:35AM
Jan-13-26 07:00AM
Jan-12-26 12:00PM
Jan-06-26 07:00AM
Jan-05-26 01:45PM
Jan-01-26 11:35AM
Dec-30-25 08:45AM
Dec-17-25 09:45AM
Dec-14-25 03:30AM
Dec-12-25 10:30AM
Dec-11-25 04:01PM
07:00AM
Dec-09-25 11:30PM
(GlobeNewswire)
-7.87%
+3.46%
02:23PM
10:43AM
Dec-08-25 04:09PM
(Investor's Business Daily)
+41.55%
04:01PM
03:10PM
01:07PM
07:42AM
07:00AM
05:32AM
Dec-05-25 04:01PM
11:30AM
Dec-04-25 11:30AM
Nov-26-25 07:33AM
Nov-25-25 07:00AM
Nov-24-25 07:00AM
Nov-04-25 08:10AM
07:00AM
Nov-03-25 07:26AM
07:00AM
Oct-28-25 07:00AM
Oct-27-25 10:00AM
07:00AM
Oct-23-25 10:00AM
Oct-01-25 09:38AM
Sep-17-25 07:00AM
Sep-16-25 12:30PM
Sep-15-25 12:15PM
Sep-07-25 10:08AM
Sep-03-25 07:00AM
Aug-27-25 07:00AM
Aug-12-25 03:04AM
Aug-11-25 08:10AM
07:00AM
Aug-08-25 09:23AM
09:20AM
Show Previous News
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Mainolfi Nello Chief Executive Officer Oct 01 '26 Option Exercise 2.08 30,000 62,400 696,568 Oct 01 05:20 PM Mainolfi Nello Chief Executive Officer Oct 01 '26 Sale 113.80 30,000 3,413,917 666,568 Oct 01 05:20 PM Mainolfi Nello Officer Oct 01 '26 Proposed Sale 111.79 30,000 3,353,700 Oct 01 04:10 PM Adams Brian Chief Legal Officer Sep 04 '26 Sale 116.83 6,371 744,297 50,254 Sep 04 06:00 PM Brian Adams Officer Sep 04 '26 Proposed Sale 117.28 6,371 747,191 Sep 04 04:15 PM JEREMY CHADWICK Officer Sep 02 '26 Proposed Sale 119.05 10,879 1,295,145 Sep 02 04:32 PM Mainolfi Nello Chief Executive Officer Jul 07 '26 Option Exercise 2.08 50,000 104,000 716,568 Jul 07 08:00 PM Mainolfi Nello Chief Executive Officer Jul 07 '26 Sale 119.00 50,000 5,950,000 666,568 Jul 07 08:00 PM Mainolfi Nello Officer Jul 07 '26 Proposed Sale 119.00 50,000 5,950,000 Jul 07 04:07 PM Jacobs Bruce N. Chief Financial Officer Jun 30 '26 Option Exercise 5.33 61,378 327,145 321,992 Jul 02 06:30 PM Jacobs Bruce N. Chief Financial Officer Jun 30 '26 Sale 114.96 77,109 8,864,829 244,883 Jul 02 06:30 PM Goodman Noah Chief Business Officer Jul 01 '26 Sale 114.29 3,389 387,329 47,179 Jul 02 06:30 PM Mainolfi Nello Chief Executive Officer Jul 01 '26 Option Exercise 2.08 80,000 166,400 746,568 Jul 02 06:30 PM Mainolfi Nello Chief Executive Officer Jul 01 '26 Sale 115.29 80,000 9,223,527 666,568 Jul 02 06:30 PM Mainolfi Nello Officer Jul 01 '26 Proposed Sale 114.29 80,000 9,143,200 Jul 02 08:33 AM NOAH GOODMAN Officer Jul 01 '26 Proposed Sale 114.67 3,389 388,617 Jul 01 04:58 PM Booth Bruce Director Jun 29 '26 Sale 109.48 31,283 3,424,800 461,794 Jun 30 05:32 PM Booth Bruce Director Jun 26 '26 Sale 110.29 467,878 51,603,032 472,267 Jun 30 05:30 PM Booth Bruce Director Jun 29 '26 Sale 107.06 45,367 4,857,104 466,077 Jun 30 05:30 PM BRUCE N. JACOBS Officer Jun 30 '26 Proposed Sale 109.32 77,109 8,429,556 Jun 30 04:32 PM Atlas Venture Opportunity Fund Shareholder Jun 29 '26 Proposed Sale 108.12 10,473 1,132,341 Jun 29 05:51 PM Atlas Venture Fund X, LP Shareholder Jun 29 '26 Proposed Sale 108.12 66,177 7,155,057 Jun 29 05:51 PM BVF PARTNERS L P/IL Director Jun 26 '26 Sale 106.50 1,578,800 168,142,200 240,123 Jun 26 06:48 PM BVF PARTNERS L P/IL Director Jun 26 '26 Sale 106.50 51,858 5,522,877 78,787 Jun 26 06:48 PM BVF PARTNERS L P/IL Affiliate of Director Jun 26 '26 Proposed Sale 116.46 1,630,658 189,906,431 Jun 26 06:13 PM Atlas Venture Fund X, LP Shareholder Jun 26 '26 Proposed Sale 116.46 410,427 47,798,328 Jun 26 04:52 PM Atlas Venture Opportunity Fund Shareholder Jun 26 '26 Proposed Sale 116.46 57,451 6,690,743 Jun 26 04:51 PM Booth Bruce Director Jun 25 '26 Sale 121.86 285,684 34,812,909 529,718 Jun 25 09:56 PM Booth Bruce Director Jun 25 '26 Sale 115.39 262,637 30,306,107 564,668 Jun 25 09:55 PM Booth Bruce Director Jun 24 '26 Sale 100.51 134,720 13,540,476 597,047 Jun 25 09:55 PM Booth Bruce Director Jun 23 '26 Sale 99.98 1,408 140,772 613,589 Jun 25 09:55 PM Goodman Noah Chief Business Officer Jun 25 '26 Option Exercise 21.05 5,000 105,250 55,195 Jun 25 06:00 PM Goodman Noah Chief Business Officer Jun 25 '26 Sale 114.00 5,000 570,000 50,195 Jun 25 06:00 PM Atlas Venture Opportunity Fund Shareholder Jun 25 '26 Proposed Sale 99.87 67,329 6,724,147 Jun 25 05:26 PM Atlas Venture Fund X, LP Shareholder Jun 25 '26 Proposed Sale 99.87 480,992 48,036,671 Jun 25 05:25 PM NOAH GOODMAN Officer Jun 25 '26 Proposed Sale 99.87 5,000 499,350 Jun 25 04:27 PM Atlas Venture Fund X, LP Shareholder Jun 24 '26 Proposed Sale 98.25 118,178 11,610,988 Jun 24 05:30 PM Atlas Venture Opportunity Fund Shareholder Jun 24 '26 Proposed Sale 98.25 16,542 1,625,252 Jun 24 05:29 PM Atlas Venture Opportunity Fund Shareholder Jun 23 '26 Proposed Sale 99.45 173 17,205 Jun 23 06:14 PM Atlas Venture Fund X, LP Shareholder Jun 23 '26 Proposed Sale 99.45 1,235 122,821 Jun 23 06:14 PM Booth Bruce Director Jun 22 '26 Sale 103.75 31,798 3,299,037 613,762 Jun 22 09:02 PM Booth Bruce Director Jun 17 '26 Option Exercise 20.00 11,741 234,820 11,741 Jun 22 09:01 PM Booth Bruce Director Jun 22 '26 Sale 98.52 246,330 24,268,861 617,663 Jun 22 09:01 PM Booth Bruce Director Jun 18 '26 Sale 91.01 115,056 10,471,661 647,914 Jun 22 09:01 PM Booth Bruce Director Jun 17 '26 Sale 90.38 105,071 9,496,317 662,042 Jun 22 09:01 PM Booth Bruce Director Jun 17 '26 Sale 89.98 11,741 1,056,455 0 Jun 22 09:01 PM Goodman Noah Chief Business Officer Jun 22 '26 Option Exercise 21.05 2,500 52,625 52,695 Jun 22 05:47 PM Goodman Noah Chief Business Officer Jun 22 '26 Sale 99.00 2,500 247,500 50,195 Jun 22 05:47 PM Atlas Venture Opportunity Fund Shareholder Jun 22 '26 Proposed Sale 90.43 34,152 3,088,365 Jun 22 05:28 PM Atlas Venture Fund X, LP Shareholder Jun 22 '26 Proposed Sale 90.43 243,976 22,062,750 Jun 22 05:28 PM NOAH GOODMAN Officer Jun 22 '26 Proposed Sale 90.43 2,500 226,075 Jun 22 04:46 PM Atlas Venture Opportunity Fund Shareholder Jun 18 '26 Proposed Sale 89.90 14,128 1,270,107 Jun 18 05:35 PM Atlas Venture Fund X, LP Shareholder Jun 18 '26 Proposed Sale 89.90 100,928 9,073,427 Jun 18 05:35 PM Atlas Venture Opportunity Fund Shareholder Jun 17 '26 Proposed Sale 87.44 12,902 1,128,151 Jun 17 05:26 PM Atlas Venture Fund X, LP Shareholder Jun 17 '26 Proposed Sale 87.44 92,169 8,059,257 Jun 17 05:25 PM Bruce Booth Director Jun 17 '26 Proposed Sale 87.44 11,741 1,026,633 Jun 17 05:25 PM JEREMY CHADWICK Officer Jun 17 '26 Proposed Sale 87.44 66,893 5,849,124 Jun 17 04:43 PM Jacobs Bruce N. Chief Financial Officer Jun 02 '26 Option Exercise 2.08 12,653 26,318 260,241 Jun 03 07:30 AM Chadwick Jeremy G Chief Operating Officer May 26 '26 Sale 79.36 12,905 1,024,194 48,297 May 27 05:50 PM Chadwick Jeremy G Chief Operating Officer May 27 '26 Sale 81.58 4,279 349,096 44,018 May 27 05:50 PM JEREMY CHADWICK Officer May 26 '26 Proposed Sale 78.89 13,130 1,035,826 May 26 04:41 PM Chadwick Jeremy G Officer May 26 '26 Proposed Sale 78.42 4,054 317,922 May 26 04:01 PM Esposito Pamela Director May 19 '26 Option Exercise 31.20 1,000 31,200 1,000 May 19 04:05 PM Jacobs Bruce N. Chief Financial Officer May 18 '26 Option Exercise 2.08 15,000 31,200 247,588 May 19 07:30 AM Ridloff Elena Director May 11 '26 Option Exercise 31.20 3,000 93,600 3,000 May 11 04:58 PM Ridloff Elena Director May 11 '26 Sale 87.00 3,000 261,000 0 May 11 04:58 PM ELENA RIDLOFF Director May 11 '26 Proposed Sale 86.08 3,000 258,240 May 11 04:35 PM Mainolfi Nello Chief Executive Officer Apr 29 '26 Option Exercise 2.08 30,000 62,400 696,195 Apr 29 05:00 PM Mainolfi Nello Chief Executive Officer Apr 29 '26 Sale 81.18 30,000 2,435,377 666,195 Apr 29 05:00 PM Mainolfi Nello Officer Apr 29 '26 Proposed Sale 82.47 30,000 2,474,100 Apr 29 04:07 PM Booth Bruce Director Apr 22 '26 Option Exercise 14.44 5,900 85,169 5,900 Apr 24 04:33 PM Booth Bruce Director Apr 22 '26 Sale 89.96 5,900 530,764 0 Apr 24 04:33 PM Booth Bruce Director Apr 22 '26 Sale 90.08 100 9,008 674,944 Apr 24 04:33 PM Chadwick Jeremy G Chief Operating Officer Apr 22 '26 Option Exercise 39.06 300 11,717 61,502 Apr 24 04:30 PM Chadwick Jeremy G Chief Operating Officer Apr 22 '26 Sale 90.00 300 27,000 61,202 Apr 24 04:30 PM Atlas Venture Fund X, LP Shareholder Apr 22 '26 Proposed Sale 88.07 88 7,750 Apr 22 04:52 PM Atlas Venture Opportunity Fund Shareholder Apr 22 '26 Proposed Sale 88.07 12 1,057 Apr 22 04:52 PM JEREMY CHADWICK Officer Apr 22 '26 Proposed Sale 88.07 300 26,421 Apr 22 04:30 PM Goodman Noah Chief Business Officer Apr 14 '26 Sale 90.00 1,347 121,230 50,195 Apr 16 06:30 PM Chadwick Jeremy G Chief Operating Officer Apr 14 '26 Option Exercise 32.16 5,251 168,887 66,453 Apr 16 06:30 PM Chadwick Jeremy G Chief Operating Officer Apr 15 '26 Option Exercise 43.50 1,300 56,550 62,502 Apr 16 06:30 PM Chadwick Jeremy G Chief Operating Officer Apr 14 '26 Sale 90.00 5,251 472,598 61,202 Apr 16 06:30 PM Chadwick Jeremy G Chief Operating Officer Apr 15 '26 Sale 90.00 1,300 117,000 61,202 Apr 16 06:30 PM Booth Bruce Director Apr 14 '26 Option Exercise 14.18 4,159 58,975 4,159 Apr 16 06:16 PM Booth Bruce Director Apr 15 '26 Option Exercise 14.18 2,200 31,196 2,200 Apr 16 06:16 PM Booth Bruce Director Apr 14 '26 Sale 89.97 4,159 374,185 0 Apr 16 06:16 PM Booth Bruce Director Apr 15 '26 Sale 90.10 3,135 282,464 674,956 Apr 16 06:16 PM Booth Bruce Director Apr 15 '26 Sale 89.95 2,200 197,890 0 Apr 16 06:16 PM Atlas Venture Opportunity Fund Shareholder Apr 15 '26 Proposed Sale 89.87 385 34,600 Apr 15 04:51 PM Atlas Venture Fund X, LP Shareholder Apr 15 '26 Proposed Sale 89.87 2,750 247,142 Apr 15 04:51 PM JEREMY CHADWICK Officer Apr 15 '26 Proposed Sale 89.86 1,300 116,824 Apr 15 04:41 PM Bruce Booth Director Apr 14 '26 Proposed Sale 88.53 24,000 2,124,720 Apr 14 05:19 PM JEREMY CHADWICK Officer Apr 14 '26 Proposed Sale 88.53 5,251 464,871 Apr 14 04:37 PM Goodman Noah Chief Business Officer Apr 09 '26 Option Exercise 21.05 2,500 52,625 61,806 Apr 10 04:45 PM Goodman Noah Chief Business Officer Apr 09 '26 Sale 87.50 8,264 723,082 53,542 Apr 10 04:45 PM Goodman Noah Chief Business Officer Apr 10 '26 Sale 87.35 2,000 174,700 51,542 Apr 10 04:45 PM Noah Goodman Officer Apr 09 '26 Proposed Sale 87.35 11,611 1,014,221 Apr 09 04:28 PM Chadwick Jeremy G Chief Operating Officer Apr 01 '26 Option Exercise 29.64 14,640 433,930 75,842 Apr 01 07:00 PM Chadwick Jeremy G Chief Operating Officer Mar 31 '26 Option Exercise 29.64 7,600 225,264 68,802 Apr 01 07:00 PM Ridloff Elena Director Mar 31 '26 Option Exercise 14.18 7,400 104,932 7,400 Apr 01 07:00 PM
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of human diseases through the development of innovative, highly differentiated medicines. It focuses on discovering and developing novel small-molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's natural protein degradation system. The company leverages targeted protein degradation (TPD) to develop medicines that address critical health challenges and have the potential to significantly improve patients lives. Its pipeline emphasizes oral small-molecule degraders, offering a new generation of convenient and highly effective therapies. The company was founded by Bruce Lee Booth and Nello Mainolfi on September 29, 2015 and is headquartered in Watertown, MA.
Ph.D. Dr. Nello Mainolfi M.D.
Chief Financial Officer Mr. Bruce N. Jacobs CFA
Chief Legal Officer & Corporate Secretary Mr. Brian R. Adams J.D.
Advisor Dr. Jared A. Gollob M.D.
Chief Business Officer Mr. Noah Goodman M.B.A.